Abstract:Objective To study the clinical significance on the combined determination of serum N-terminal pro-B-type natriuretic peptide (NT-proBNP),heart-type fatty acid-binding protein(H-FABP)and cardiac troponin I(cTnI)in elder patients with severe heart failure (HF ).Methods The serum NT-proBNP,H-FABP and cTnI levels were determined in 31 2 elder patients with severe HF {main adverse cardiovascular event (MACE )group (1 94 cases ) [cardiogenic readmission group(1 1 0 cases)and death group(84 cases)]and no-MACE group(1 1 8 cases)}on admission, day 7,1 5,30 and 60 after treatment,76 elder patients with no-severe HF and 40 elder healthy subjects.The MACE were followed and observed for 1 80 d.The significance of NT-proBNP,H-FABP and cTnI for the diagnosis of severe HF and the prediction of death risk was analyzed by receiver operating characteristic(ROC)curve.Survival analysis was performed by Kaplan-Meier curve.Results The serum NT-proBNP,H-FABP and cTnI levels in elder patients with severe HF were significantly higher than those in elder patients with no-severe HF and healthy subjects (P<0.01 ),the positive rate of H-FABP in elder patients with no-severe HF was 47.1%,and the positive rate of cTnI was 4.5%.The serum NT-proBNP levels were positively correlated with the grade of New York Heart Association (NYHA)Ⅰ-Ⅳ(r=0.77,P<0.01 ).The ROC curve indicated that the optimal cut-off values of serum NT-proBNP,H-FABP and cTnI levels for diagnosis in elder patients with severe HF were 4 601 .50 ng/L,5.1 6 ng/L and 0.025 ng/mL,and the optimal cut-off values of serum NT-proBNP,H-FABP and cTnI levels for the death risk evaluation in elder patients with severe HF were 8 1 78.50 ng/L, 1 1 .77ng/L and 0.038ng/mL,respectively.The sensitivity of the combined determination was obviously better than those of the individual determinations (P<0.05 ).Before the treatment,the serum NT-proBNP levels in MACE group were significantly higher than those in no-MACE group(P<0.05),the serum H-FABP levels in death group were significantly higher than those in no-death group(P<0.05 ),and the serum cTnI levels in various prognosis groups had no statistical significance (P>0.05 ).The serum NT-proBNP,H-FABP and cTnI levels in no-MACE group on day 7 after treatment were significantly lower than those before the treatment (P<0.05 ).The decreasing rates of the 3 parameters were >50%,and the serum H-FABP level was lower than the normal reference value.The serum NT-proBNP,H-FABP and cTnI levels in the cardiogenic readmission group on day 1 5 after treatment were significantly lower than those before treatment (P<0.05),but the decreasing rates of the 3 parameters were <30%,and the serum H-FABP level was higher than the normal reference value.The serum NT-proBNP,H-FABP and cTnI levels in death group on day 7 and day 30 after treatment were significantly higher than those before treatment(P<0.05),and the serum cTnI levels were higher than the normal reference value.Kaplan-Meier survival curve showed that the survival rates of serum NT-proBNP,H-FABP and cTnI levels had significant difference (P <0.05 ).Conclusions There is an important clinical significance of the combined determination of serum NT-proBNP,H-FABP and cTnI levels for the diagnosis,prognosis,death risk evaluation and curative effect survey in elder patients with severe HF.

Correlation Between ACE2 ,ACE2 Antibody ,Ang-(1-7 ) and NT-proBNP in Patients with Chronic Heart Failure

Expression and clinical significance of serum angiopoietin-2 in patients with chronic heart failure

Determination of N-terminal Pro-Brain Natriuretic Peptide and Other Biochemical Markers in Elderly Patients with Chronic Heart Failure

Levels and clinical significance of serum NT-proBNP, UA and hs-CRP in chronic heart failure

Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide and Glomerular Filtration Rate in Patients with Acute Heart Failure

Clinical Significance of B-Type Natriuretic Peptide and Uric Acid Levels in Patients With Chronic Congestive Heart Failure

Corelation Between Plasma N-terminal ProBNP(NT-proBNP) and Cardiac Dysfunction

Correlation of NT-proBNP levels with liver function in patients with chronic congestive heart failure

Relationship between N-terminal pro-brain natriuretic peptide and heart failure

Influencing factors for plasma natriuretic peptide and N-terminal pro-B-type natriuretic peptide levels in senior patients with heart failure

Values of plasma N-terminal pro-B-type natriuretic peptide in severity assessment and prognostic prediction for chronic heart failure in the elderly

The Relationship between Cardiac Hemodynamics and the Level of Plasma NT-proBNP in Patients with Acute Coronary Syndrome

The Clinical Significance on the Combined Determination of NT-proBNP,H-FABP and Ctni in Elder Patients with Severe Heart Failure

Changes of blood N-terminal fragment of brain natriuretic peptide prohormone in patients with chronic heart failure

The Effect of Brain Natriuretic Peptide on Serum Angiotensin-Converting Enzyme 2 Levels in Acute Heart Failure Patients with Reduced Ejection Fraction

Prognostic value of N-terminal B-type natriuretic peptide in patients with chronic heart failure

Value of Serum N-terminal Pro-B-type Natriuretic Peptide for the Diagnosis and Prognosis Evaluation in Patients with Coronary Heart Disease

The clinical significance of B-type natriuretic peptide,N-terminal pronatriuretic peptide and soluble ST2 monitoring in patients with heart failure

Application of BNP and NT-proBNP in Diagnosis of Diastolic Heart Failure

Different Etiological Factors of Heart Failure May Have Diverse Levels of Biomarkers.

Relation between three biomarkers and prognosis of heart failure